Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 17INDUSTRY 3NIH 2NETWORK 2FED 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other 1Head & Neck 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

tempol 1sodium thiosulfate 1ebselen 1Sodium Chloride 1Hyaluronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Ototoxicity × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Matrix Biomed, Inc.

Phase 2 Recruiting
120 enrolled
Other

Ototoxicity, Mucositis

NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Decibel Therapeutics

Phase 1 Completed
22 enrolled

Ototoxicity, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡